Tenax Therapeutics
Tenax Therapeutics maintains an oxygen supply to stop disease and damage to tissues that occurs when the flow of oxygen is interrupted.
Launch date
Employees
Market cap
$12.6m
Enterprise valuation
$3m (Public information from Sep 2024)
Share price
$3.62 TENX
Morrisville North Carolina (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | 1.0m | 4.2m |
% growth | - | - | - | - | - | - | 316 % |
EBITDA | (9.7m) | (32.4m) | (10.9m) | (7.7m) | - | - | - |
Profit | (9.9m) | (32.5m) | (11.0m) | (7.7m) | (16.8m) | (23.0m) | (24.1m) |
% profit margin | - | - | - | - | - | (2303 %) | (581 %) |
EV / revenue | - | - | - | - | - | 13.6x | 3.3x |
EV / EBITDA | -2.4x | -0.8x | -0.5x | -0.8x | - | - | - |
R&D budget | 4.6m | 25.1m | 5.4m | 3.2m | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $5.3m | Early VC | |
N/A | N/A | IPO | |
N/A | $5.4m | Post IPO Equity | |
* | N/A | $40.0m | Post IPO Equity |
N/A | $10.0m | Post IPO Equity | |
N/A | $5.2m | Post IPO Equity | |
N/A | $10.0m | Post IPO Equity | |
* | N/A | $8.0m | Post IPO Equity |
* | N/A | $15.6m | Post IPO Equity |
* | N/A | $9.0m | Post IPO Equity |
* | $100m | Private Placement non VC | |
Total Funding | $5.3m |
Related Content
Recent News about Tenax Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.